112 related articles for article (PubMed ID: 29168205)
1. A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers.
Okour M; Derimanov G; Barnett R; Fernandez E; Ferrer S; Gresham S; Hossain M; Gamo FJ; Koh G; Pereira A; Rolfe K; Wong D; Young G; Rami H; Haselden J
Br J Clin Pharmacol; 2018 Mar; 84(3):482-489. PubMed ID: 29168205
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
[TBL] [Abstract][Full Text] [Related]
3. Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A.
Ostenfeld T; Beaumont C; Bullman J; Beaumont M; Jeffrey P
Br J Clin Pharmacol; 2012 Dec; 74(6):1033-44. PubMed ID: 22497298
[TBL] [Abstract][Full Text] [Related]
4. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.
McCarthy JS; Rückle T; Djeriou E; Cantalloube C; Ter-Minassian D; Baker M; O'Rourke P; Griffin P; Marquart L; Hooft van Huijsduijnen R; Möhrle JJ
Malar J; 2016 Sep; 15(1):469. PubMed ID: 27624471
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion-451840 in an induced blood stage malaria study in healthy subjects.
Krause A; Dingemanse J; Mathis A; Marquart L; Möhrle JJ; McCarthy JS
Br J Clin Pharmacol; 2016 Aug; 82(2):412-21. PubMed ID: 27062080
[TBL] [Abstract][Full Text] [Related]
6. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.
Phyo AP; Jittamala P; Nosten FH; Pukrittayakamee S; Imwong M; White NJ; Duparc S; Macintyre F; Baker M; Möhrle JJ
Lancet Infect Dis; 2016 Jan; 16(1):61-69. PubMed ID: 26448141
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.
Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Brian Houston J; Oosterhuis B; Bjerrum OJ; Grynkiewicz G; Alder J; Rowland M; Garner C
Eur J Pharm Sci; 2011 Jun; 43(3):141-50. PubMed ID: 21540108
[TBL] [Abstract][Full Text] [Related]
8. Hollow-Fiber Methodology for Pharmacokinetic/Pharmacodynamic Studies of Antimalarial Compounds.
Caton E; Nenortas E; Bakshi RP; Shapiro TA
Curr Protoc Chem Biol; 2016 Mar; 8(1):29-58. PubMed ID: 26995353
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.
McCarthy JS; Baker M; O'Rourke P; Marquart L; Griffin P; Hooft van Huijsduijnen R; Möhrle JJ
J Antimicrob Chemother; 2016 Sep; 71(9):2620-7. PubMed ID: 27272721
[TBL] [Abstract][Full Text] [Related]
10. Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development.
McCarthy JS; Marquart L; Sekuloski S; Trenholme K; Elliott S; Griffin P; Rockett R; O'Rourke P; Sloots T; Angulo-Barturen I; Ferrer S; Jiménez-Díaz MB; Martínez MS; Hooft van Huijsduijnen R; Duparc S; Leroy D; Wells TN; Baker M; Möhrle JJ
Antimicrob Agents Chemother; 2016 Jun; 60(6):3669-75. PubMed ID: 27044554
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and pharmacokinetic evaluation of a novel anti-malarial compound (NP046) in a mouse model.
Abay ET; van der Westuizen JH; Swart KJ; Gibhard L; Lawrence N; Dambuza N; Wilhelm A; Pravin K; Wiesner L
Malar J; 2015 Jan; 14():8. PubMed ID: 25563929
[TBL] [Abstract][Full Text] [Related]
12. Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients.
Park WS; Park GJ; Han S; Ban S; Park MY; Kim SH; Kim SM; Kim YC; Kim HS; Shin YG; Yim DS
Cancer Chemother Pharmacol; 2017 Aug; 80(2):363-369. PubMed ID: 28660432
[TBL] [Abstract][Full Text] [Related]
13. Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.
Deye GA; Miller RS; Miller L; Salas CJ; Tosh D; Macareo L; Smith BL; Fracisco S; Clemens EG; Murphy J; Sousa JC; Dumler JS; Magill AJ
Clin Infect Dis; 2012 Jan; 54(2):232-9. PubMed ID: 22052893
[TBL] [Abstract][Full Text] [Related]
14. Application of the Stable Isotope Label Approach in Clinical Development-Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound.
Goyal N; Mohamed K; Rolfe K; Sahota S; Ernest T; Duparc S; Taylor M; Casillas L; Koh GCKW
AAPS J; 2018 Jun; 20(4):74. PubMed ID: 29869298
[TBL] [Abstract][Full Text] [Related]
15. Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria.
White NJ; Duong TT; Uthaisin C; Nosten F; Phyo AP; Hanboonkunupakarn B; Pukrittayakamee S; Jittamala P; Chuthasmit K; Cheung MS; Feng Y; Li R; Magnusson B; Sultan M; Wieser D; Xun X; Zhao R; Diagana TT; Pertel P; Leong FJ
N Engl J Med; 2016 Sep; 375(12):1152-60. PubMed ID: 27653565
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.
Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Houston B; Oosterhuis B; Bjerrum OJ; Rowland M; Garner C
Eur J Pharm Sci; 2010 May; 40(2):125-31. PubMed ID: 20307657
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria.
Ruangweerayut R; Looareesuwan S; Hutchinson D; Chauemung A; Banmairuroi V; Na-Bangchang K
Malar J; 2008 Oct; 7():225. PubMed ID: 18973702
[TBL] [Abstract][Full Text] [Related]
18. Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.
Garner CR; Park KB; French NS; Earnshaw C; Schipani A; Selby AM; Byrne L; Siner S; Crawley FP; Vaes WH; van Duijn E; deLigt R; Varendi H; Lass J; Grynkiewicz G; Maruszak W; Turner MA
Br J Clin Pharmacol; 2015 Jul; 80(1):157-67. PubMed ID: 25619398
[TBL] [Abstract][Full Text] [Related]
19. Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
Zhang YK; Plattner JJ; Easom EE; Jacobs RT; Guo D; Freund YR; Berry P; Ciaravino V; Erve JCL; Rosenthal PJ; Campo B; Gamo FJ; Sanz LM; Cao J
J Med Chem; 2017 Jul; 60(13):5889-5908. PubMed ID: 28635296
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects.
Madan A; O'Brien Z; Wen J; O'Brien C; Farber RH; Beaton G; Crowe P; Oosterhuis B; Garner RC; Lappin G; Bozigian HP
Br J Clin Pharmacol; 2009 Mar; 67(3):288-98. PubMed ID: 19523012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
